Journal
CANCER SCIENCE
Volume 108, Issue 8, Pages 1634-1639Publisher
WILEY
DOI: 10.1111/cas.13291
Keywords
Cord blood transplantation; engraftment; hematological malignancy; intrabone; non-myeloablative conditioning
Categories
Funding
- Practical Research Project for Allergic Diseases and Immunology [15ek0510010h0003]
- Japan Agency for Medical Research and Development
- KAKENHI [15K09498]
- Japan Society for the Promotion of Science
- Grants-in-Aid for Scientific Research [15K09498, 16K09868, 16H06868, 17K09921, 17K09006] Funding Source: KAKEN
Ask authors/readers for more resources
The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR >= 4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 x 10(7) /kg (range, 2.0-4.9 x 10(7) /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils >= 0.5 x 10(9) /L, reticulocytes >= 1%, and platelets >= 20 x 10(9) /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available